News
FDA Approves Denileukin Diftitox for Relapsed/Refractory Cutaneous T-Cell Lymphoma
"As a treating oncologist, I have seen the profound negative effect on the quality of life in patients with [relapsed/refractory cutaneous T-cell lymphoma],” said Dr. Francine Foss, professor of hematology and director of the multidisciplinary T-cell lymphoma program at Yale Cancer Center in New Haven, Connecticut, said in the release. “Given the long-term nature of the disease, pruritus, ulceration of the tumors, and secondary pyogenic skin infection, it is vital to get this skin involvement under control. Lymphir is the first therapeutic option in many years to offer hope of reducing skin disease, bringing us one step closer to filling the need for [cutaneous T-cell lymphoma] patients, particularly those that are not able to complete or continue prior therapies.”
Source: Oncology Nursing News